Get a Sample
Schedule a Meeting
Get a Sample
Table Of Content
July 2025
The U.S. compounding pharmacies market size is calculated at USD 6.45 billion in 2025 and is forecasted to reach around USD 10.93 billion by 2034, accelerating at a CAGR of 6.04% from 2025 to 2034. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
The U.S. compounding pharmacies market size was calculated at USD 6.10 billion in 2024 and is predicted to increase from USD 6.45 billion in 2025 to approximately USD 10.93 billion by 2034, expanding at a CAGR of 6.04% from 2025 to 2034.
The U.S. compounding pharmacies market is evolving rapidly, and artificial intelligence is making an impact on precision, efficiency and safety in compounding processes. AI-enhanced pharmacy technology is allowing pharmacists to generated highly customized medications to patients, given an analysis of a patient's data, history and potential drug interactions. This improves personalized medication accuracy and overall therapeutic outcomes.
At the same time, robots and AI-enabled automation technologies found within sterile compounding labs can supplement fast and efficient workflows, resulting in greater degrees of precision, while also reducing human errors, contamination potential, and even turn-around times. Predictive analytics also help with managing stocks, projecting medication needs, and eliminating drug waste in navigating challenges between distribution chains and drug shortages. AI can allow the management to remain in compliance by automating and analysing patient documentation, and quality assurance processes as part of ongoing declarations that need to be submitted.
The U.S. compounding pharmacies market is slowly but steadily increasing with an impressive rate of growth and is showing no signs of slowing down. Much of this growth is propelled by the increasing demand for personalized medications, meaning that each medication is individually tailored for each patient. Compounded medications are, by definition, not pre-manufactured drug products. Compounded medications are products prepared by pharmacists to meet an individual's specific needs, changing strength of dosing, altering route of administration, omitting allergens or unnecessary excipients, or combining active ingredients into one product.
Personalized approaches to health care are necessary in specialty areas such as pain syndromes, dermatology, hormone replacement therapy (HRT), pediatrics, and oncology where standard medications do not provide the best opportunity for success. Compounded solutions fill an essential gap that commercial drugs leave behind as the burden of chronic disease and polypharmacy issues continue to rise.
What are the Upcoming Trends in Compounding Pharmacies Market?
The increasing demand for integrative and functional medicine that embraces personalized, holistic care creates sustained demand for compounded medications in hospital and specialty clinics and wellness-focused pharmacies. Healthcare practitioners and patients are more aware of the clinical flexibility and therapeutic indications of compounded medications, which provides market entrenchment and increased acceptance. Coupled with ongoing trust and technological advances involving pharmacy automation and reducing the regulatory fog, compounding medication will continue to support and advance the fabric of healthcare delivery in the U.S.
The surging investments by the key market players in the research and development to innovate and customize the formulations to effectively treat various diseases are expected to boost the growth of the US compounding pharmacies market. The growing prevalence of cancer among the US population is significantly augmenting the market growth.
According to the National Cancer Institute, in 2020, approximately 1,806,590 new cancer cases were estimated to be diagnosed and about 606,520 cancer deaths were estimated in US. The most diagnosed type of cancer included breast cancer, lungs cancer, prostate cancer, and colon and rectum cancer. The lungs, prostate, and colorectal cancer collectively accounted for 43% of the total new cancer cases diagnosed in men, while in women, the breast, lungs, and colorectal cancer accounted for 50% in 2020. The cancer incidence or rate of new cancer cases in men is 442.4 per 100,000. The cancer death rate is 158.3 per 100,000 per year. It was estimated that around 16,850 adolescents and children aged 0 to 19 years would be diagnosed with cancer and around 1,730 would die out of it in 2020. US$150.8 billion was estimated to be the national cancer care expenditure in US in 2018.
Therefore, the surging cases of cancer in US are expected to significantly boost the growth of the US compounding pharmacies market in the forthcoming years. There has been a shortage of drugs owing to the longer lead times, lack of adequate raw materials, increased drug failure, and delayed production, which is a prominent factor behind the growth of the US compounding market. Furthermore, growing geriatric population base in US along with the better longevity is accelerating the market growth significantly. According to the Population Reference Bureau, by 2060, the geriatric population in US will constitute around 24% of the total US population.
The increasing acceptance of compounding pharmacies and the presence of favorable government policies pertaining to reimbursements is driving the growth of the US compounding pharmacies market. Further, the rising technological advancements is leading to the growth of the effective compounding pharmacies. The presence of leading market players coupled with the presence of strong healthcare infrastructure in US is augmenting the growth of the US compounding pharmacies market.
| Report Coverage | Details |
| Growth Rate from 2025 to 2034 | CAGR of 6.04% |
| Market Size in 2025 | USD 6.45 Billion |
| Market Size by 2034 | USD 10.93 Billion |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
| Segments Covered | Pharmacy Type, Product, Sterility, Compounding Type, Therapeutic Area, and End-User |
Rising Emphasis over Personalized Therapeutics
The growing demand for personalized therapeutics represents a significant opportunity in the compounding pharmacy marketplace across several niche areas including pediatric dosing, veterinary compounding, hormone optimization, and dermatological applications. Patients and providers (prescribers) are recognizing and requesting customized formulations that meet their unique needs, allergies, and dosing where appropriate, leading to a shift away from traditional one-size-fits-all pharmaceuticals to adopting precision-based care.
Advanced Technologies
With automation, automated compounding systems driven by AI, and robotics, pharmacies can provide scalable, sterile medications of high-quality, and with more accurate and consistent outcomes now more than ever. Collaborations with telehealth partners, concierge medicine organizations, and specialty clinics are allowing access to patients and channeling new ways for compounding pharmacy organizations to acquire new patients outside their geography.
These collaborations are especially relevant when utilizing telehealth services to get medications or customized formulations that do not exist during the ongoing national shortage of pharmaceuticals, which can keep compounding pharmacies relevant to current patient care provision. Digital transformations (e-commerce websites, online consultations, and apps) that provide a more convenient, compliant, and accessible way in providing customized formulations is catering to patients' needs.
Stringent Regulatory Framework and High Cost:
Increased compliance costs and burdensome regulatory frameworks related to evolving FDA and USP guidance will continue to constrain U.S. compounding pharmacies operationally and financially. Compliance with these stringent standards, especially the sterile compounding requirements, constantly require investment in improvements to the facility and ongoing staff training and documentation, and adds overhead for smaller pharmacies and limits their scaling ability.
Quality control challenges only bring a higher risk of liability in a market with products that have to meet absolute sterility and exacting specifications, like injectables or ophthalmic products. And with inflexible reimbursement and ambiguous insurance coverage limiting profitability, it is challenging for providers to justify offering a compounded alternative to a mass-produced pharmaceutical. Providers often shift the financial risk of a compounded medication back to the patient because of the lack of consistent reimbursement, which is a primary impediment to wide-scale utilization. With emerging competition from large pharmaceutical manufacturers releasing pre-formulated drugs aimed at previously compounded only indications, the market pressure is only adding constraints.
Automation & Business Activities
There are opportunities for automation, and AI-based precision to drive scalable opportunities with fewer errors and improved quality. Through strategic partnerships with telehealth provider and specialty clinics we can access new patients. Supporting gaps in therapeutic options may be another growth path as we're back into drug shortages. The future is digital, and through e-commerce we can create digital options and access that improves patient access, as well as further streamline the prescription workload across the U.S.
Based on product, the oral medications segment dominated the US compounding pharmacies market, accounting for around 36.21% of the market share in 2024. The rising prevalence of various chronic diseases and increased preference for oral medications owing to their ease of use and easy storage have boosted the growth of this segment. The availability of various oral medications in the form of tablets, capsules, powder, and granules are some of the major and most preferred traditional forms of oral medications. The increasing demand for personalized medications among the various age groups is expected to foster the growth of the market in the upcoming years.
Liquid Preparations segment accounted for around 22.94% of the US compounding pharmacies market share in 2024 and is expected to be the fastest-growing segment during the forecast period. For doctors looking for a substitution for the more popular oral solid dose type, oral liquid solutions offer a versatile option. Compounding pharmacies may be required to manufacture oral liquids if an oral solid dose form is incorrect for a particular patient or if providing the patient's desired dosage is difficult. Tablets and prescriptions are typically difficult to swallow for children and the elderly. Due to liquid pharmaceuticals offering a more pleasant formulation & an easier delivery mechanism, these patient populations are able to consume their medications more readily. Patients occasionally require prescriptions that are not available over the counter, as well as certain drug combinations. Compounding chemists may develop these unique mixtures in liquid form to meet the needs of the patient.
Based on the pharmacy type, the 503A segment dominated the US compounding market in 2024. This segment is estimated to grow at a CAGR of 6.08% during the forecast period. The government restrictions on drug production and requirements of medicine prescriptions have led to the growth of the 503A segment in the market. It is highly used for domestic consumption and hence dominates the US market. The strict regulations for biannual monitoring and audit ensure the safety and quality of this product.
U.S. Compounding Pharmacies Market Revenue, By Pharmacy Type, 2022-2024 (USD Billion)
| By Pharmacy Type | 2022 | 2023 | 2024 |
| 503A |
3.99 | 4.21 | 4.45 |
| 503B |
1.49 | 1.57 | 1.65 |
Depending on the sterility, the US compounding pharmacies market was dominated by the non-sterile segment that accounted for a market share of around 5.85% in 2024.
The sterile segment is expected to witness the highest growth rate during the forecast period. The rising incidences of chronic ailments like cancer and cardiovascular diseases are expected to significantly drive the growth of the sterile segment in the upcoming future. The growing demand for the sterile compounding pharmacies owing to the increasing adoption of ophthalmic and parenteral medications is further fueling the growth of the segment during the forecast period
U.S. Compounding Pharmacies Market Revenue, By Sterility, 2022-2024 (USD Billion)
| By Sterility | 2022 | 2023 | 2024 |
| Sterile | 1.53 | 1.62 | 1.71 |
| Non-Sterile |
3.95 | 4.16 | 4.39 |
Others include, oncology, haematology, dental, and others. According to the International Diabetes Federation (IDF), there will be 537 million adult diabetics globally in 2021, rising to 643 million by 2030. Cancer patients are harder to live with than the disease itself. The adverse effects of chemotherapy can make patients weak and compromise their overall health, making other medications a complicated issue. Thus, oncology compounding is used by the doctor and prescribes a particular combination of drugs and treatments to meet patients' needs, minimizing the amount of time and effort a patient has to take medications. Innovative formulations such as mouthwash or topical creams are used to produce drugs who suffer from nausea, cannot swallow pills, or have other conditions that make traditional dosage difficult. Moreover, using topical medications decreases the effectiveness lost through absorption during the digestive process and the potential for adverse interaction with cancer treatment. Similarly, with dental compounding unpleasant experiences and anxiety from patients can be removed, when the dentist and pharmacist work together. Dental compounding has grown more popular in recent years because many variables go into a dental procedure. Dental compounding is the practice of developing customized medications for your dental needs. These customized medications are prescribed for procedural anxiety, pain relief, gum disease, mouth ulcers, and many others. Thus, the growing applications of others in compound pharmacies are likely to enhance market growth during the forecast period.
The pain management segment reached at USD 0.54 billion in 2024 and is projected to grow at a CAGR of 6.10% from 2025 to 2034. Pain is the most obvious symptom for which patients explore medical help. Acute pain can easily grow into chronic pain, which later becomes difficult to treat. Commercially convenient pain relief medications can treat chronic conditions such as arthritis, fibromyalgia, migraine, and other nerve and muscle pain; however, these medication can grow undesired side effects such as dizziness, drowsiness, or stomach irritation. Therefore, many patients seek a more suitable solution through pharmacy compounding.
U.S. Compounding Pharmacies Market Revenue, By Therapeutic Area, 2022-2024 (USD Billion)
| By Therapeutic Area | 2022 | 2023 | 2024 |
| Hormone Replacement | 1.05 | 1.17 | 1.17 |
| Pain Management | 0.48 | 0.51 | 0.54 |
| Dermatology | 0.25 | 0.26 | 0.28 |
| Pediatrics | 0.19 | 0.20 | 0.21 |
| Urology | 0.15 | 0.16 | 0.17 |
| Others | 0.54 | 0.56 | 0.58 |
In the U.S. compounding pharmacies market, hospitals continue to dominate the end-user market segment and are followed by home healthcare due to their continual need for sterile and personalized medication in times of critical care and monitoring chronic conditions. Hospitals utilize compounding pharmacies for on-demand medications, high-quality injectables, IV injectable therapies, and specialized medications and treatments, as they are often unavailable in commercial forms.
Home care is also beginning to rely more on compounded medications, as home healthcare services strive to ensure patient adherence, improve patient health outcomes, and aid in the comfort of those individuals receiving long-term care, which applied to elderly individuals and immunocompromised patients, to help alleviate pain levels and dependency on injected medications.
Country Analysis:
With an infrastructure that supports advanced healthcare, high demand for personalized medicine, and patient-centred care, the U.S. is the global leader in the compounding pharmacies market. The growing aging population and the increase in chronic disease conditions in the United States had increased the need for customized medications that mass-produced medications traditionally do not accommodate. Compounding pharmacies in the United States are increasingly providing compounded medications associated with specific patient needs through not reuse allergen medications, delivering medications in a manageable dosing while providing patient-specific medications that are not commercially manufactured.
It is estimated that states like Texas, California, and Florida will continue to be critical operations bases for advancing compounding pharmacies due to the volume of specialty clinics, their aging population and supportive regulators. Advances associated with artificial intelligence and automation in the compounding pharmacy industry are also a benefit to improve accuracy, sterility, and efficiency in operations. Furthermore, the growing use of and awareness associated with functional medicine, hormone replacement therapies, and alternative treatment options also reverberant the increased use of compounding pharmacy services.
(Source- https://fagron.com)
(Source- https://www.empowerpharmacy.com)
(source- https://www.fda.gov)
By Pharmacy Type
By Product
By Sterility
By Compounding Type
By Therapeutic Area
By End-User
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
July 2025
March 2025
April 2024
August 2024